Analyst Reco. NeueHealth, Inc.

Equities

NEUE

US10920V4041

Market Closed - Nyse Other stock markets 21:10:00 26/04/2024 BST			5-day change	1st Jan Change
6.11 ^USD	-3.54%		+4.98%	-19.92%

04-10	NeueHealth Amends Credit Facility to Raise Loan Commitment by $30 Million, Plans to Issue Warrants	MT
04-09	NeueHealth, Inc. Enters into an Incremental Amendment to its Credit Facility with New Enterprise Associates	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Raises Price Target on NeueHealth to $8 From $7 on Improving Liquidity, Keeps Sector Perform Rating	03-13	MT
RBC Lifts PT on Bright Health Group to $16 From $13 After 'Solid' Results From Continuing Operations, Notes Easing Liquidity Concerns; Sector Perform Kept	14/08/23	MT
Nephron Research Upgrades Bright Health to Buy From Hold, Raises Price Target to $85 From $27	30/06/23	MT
Barclays Downgrades Bright Health Group to Underweight From Overweight	15/06/23	MT
RBC Slashes Price Target on Bright Health Group to $13 From $80, Cites Ongoing Liquidity Concerns, Keeps Sector Perform Rating	30/05/23	MT
Morgan Stanley Adjusts Price Target on Bright Health to $160 From $2, Maintains Underweight Rating	19/05/23	MT
Goldman Sachs Downgrades Bright Health Group to Sell From Neutral With $0.50 Price Target	13/12/22	MT
Citigroup Adjusts Bright Health Group's Price Target to $1.20 From $2.25, Keeps Neutral Rating	16/11/22	MT
JPMorgan Downgrades Bright Health Group to Underweight From Neutral	12/10/22	MT
Piper Sandler Adjusts Price Target on Bright Health Group to $3 From $5, Reiterates Overweight Rating	11/08/22	MT
BofA Securities Adjusts Bright Health Group Price Target to $1 From $1.50, Maintains Underperform Rating	15/06/22	MT
BofA Securities Assess Risks to Managed Care Sector Amid Shifting Regulatory Environment, Market Disruption	26/05/22	MT
JPMorgan Downgrades Bright Health Group to Neutral From Overweight; Price Target is $2	29/03/22	MT
Bright Health Group Downgraded to Sector Perform From Outperform by RBC, Price Target Slashed to $3 From $9 After Q4 Miss	04/03/22	MT
Barclays Adjusts Bright Health Group's Price Target to $4 From $5.50, Reiterates Overweight Rating	03/03/22	MT
Goldman Sachs Adjusts Bright Health Group Price Target to $3.50 From $5, Maintains Neutral Rating	03/03/22	MT
Cowen & Co Adjusts Bright Health Group Price Target to $3 From $6, Maintains Market Perform Rating	03/03/22	MT
BofA Securities Downgrades Bright Health Group to Underperform From Buy, Adjusts Price Target to $2.50 From $6	03/03/22	MT
Piper Sandler Adjusts Price Target on Bright Health Group to $5 From $10, Reiterates Overweight Rating	03/03/22	MT
Barclays Lowers Price Target for Bright Health Group to $5.50 From $9, Maintains Overweight Rating	07/01/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. NeueHealth, Inc.

Equities

NEUE

US10920V4041

Analyst Reco.

Filters